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(C0) MONITORING OF NEORAL: AN ECONOMIC EVALUATION
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OBJECTIVES: Monitoring of Neoral by 2-hour post-dose
cyclosporine (CsA) levels (C2) is an accurate measure of CsA
absorption efﬁciency and exposure. It is superior to trough (C0)
monitoring for prediction of rejection risk and for targeting
optimal CsA doses. Our goal was to assess potential economic
beneﬁts of C2 monitoring by the use of an economic model.
METHODS: Parameter estimates for key clinical events were
derived from two cohorts containing 296 patients for C2 moni-
toring and 204 for C0 monitoring. An economic model was
developed to calculate treatment costs according to different clin-
ical outcomes. This multiple regression model is based on
resource utilization records of kidney transplanted patients at
Medizinische Hochschule Hannover. RESULTS: The incidence of
clinically conﬁrmed acute rejection (CAR) at 3 months post-
transplant was 28.2% for patients monitored by C0 and 15.3%
for C2. Delayed graft function (DGF) and graft failure occurred
in 32.4% and 4.4% of the C0 population and 36.5% and 4.9%
of the C2 population, respectively. These events resulted in a
highly signiﬁcant increment on 3-months treatment costs, i.e.
5424€ (DGF), 6362€ (CAR) and 14,117€ (graft failure) com-
pared to problem-free patients. Average direct three-months
treatment costs were 22,583€ for C0 and 20,650€ for C2
cohorts. CONCLUSION: Use of C2 monitoring produces not
only clinically important beneﬁts but also provides an estimated
saving of 1933€ during the ﬁrst 3 months after transplantation.
Therefore, C2 promises to be a superior patient management
strategy over C0 monitoring. The model developed allows a pre-
liminary assessment of the short-term economic impact of C2
monitoring.
PUK9
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OBJECTIVES: Immunosuppresive therapy is required to prevent
graft rejection. Older medicines such as tacrolimus are para-
doxically toxic to the kidney, whereas newer therapies such as
sirolimus (Rapamune) are not. The purpose of this study was to
evaluate the relative cost-utility of sirolimus versus tacrolimus in
the UK. METHODS: A stochastic simulation model was con-
structed using clinical trial and real-life data comparing the two
treatments. Time duration was up to 20-years, 2003 prices, dis-
counted at 6% for costs and 1.5% beneﬁts and from an NHS
perspective. Simulated events included patient and graft survival,
haemodialysis, peritoneal dialysis, re-transplants and acute rejec-
tion. Costs were summed for events and various maintenance
therapies. Utility was differentially accredited depending upon
survival using the alternative renal replacement therapies.
Outcome was predicted using post-transplant creatinine levels up
to 3-years. Extensive statistical economic analysis and sensitiv-
ity analysis was undertaken. RESULTS: Extensive validation
demonstrated that the simulation was very reliable. Over the 10-
year horizon, sirolimus gained 0.58yrs (discounted) of function-
ing graft over tacrolimus, resulting in an incremental cost per
year of functioning graft that was dominant (ICER was calcu-
lated at -£39,576). Over a 20-year time horizon cost effective-
ness of sirolimus over tacrolimus further improved with an
average discounted gain in years of a functioning graft of 1.5yrs,
resulting in an incremental cost-utility that was dominant (ICUR
-£46,695). The number of haemodialysis events was 48,243 on
sirolimus versus 127,829 129, on tacrolimus and peritoneal dial-
ysis events 40,872 versus 105,249, respectively. Sirolimus
remained dominant over tacrolimus under all scenarios. This
ﬁndings were robust using statistical economic analysis and sen-
sitivity analysis. CONCLUSIONS: Sirolimus was far more cost-
effective than tacrolimus and was economically “dominant”.
The magnitude of this difference indicates that this ﬁnding is
likely to be geographically generalisable.
PUK10
A HEALTH ECONOMIC EVALUATION OF 6 MONTHS
ALFUZOSIN TREATMENT IN THE MANAGEMENT OF ACUTE
URINARY RETENTION
Lamotte M, Cleemput I,Annemans L
HEDM, Meise, Belgium
OBJECTIVES: An important complication of Benign Prostate
Hyperplasia is Acute Urinary Retention (AUR). This condition
needs acute catheterisation and is a predisposing factor for
surgery. Subsequent removal of the catheter is only possible in a
minority of patients. Moreover, after removing the catheter the
long-term prostatectomy rate is considerable. Alfuzosin increases
the success rate of catheter removal, and may decrease the need
for future surgery. This study assessed the cost-consequences of
treating patients with AUR with alfuzosin, watchful waiting or
immediate prostatectomy from the perspective of the National
Health Service (NHS) in the UK. METHODS: Starting from the
treatment path and the immediate and 6-month clinical outcome
of the trial programme “ALFAUR”, a medical decision model to
compare the cost-consequences of watchful waiting, immediate
prostatectomy and alfuzosin treatment was built in Excel MS
2000. The time horizon of the model was 6 months. Cost data
were obtained from the NHS and resource use data gathered
alongside the clinical trial. A Monte Carlo analysis, allowing
variability in all uncertain parameters of the model, was per-
formed to calculate the uncertainty surrounding the results. The
unit cost of alfuzosin was £0.79. Patients were continued on alfu-
zosin for 6 months if the catheter was removed successfully.
RESULTS: Treating patients with alfuzosin during initial hospi-
talisation for AUR and during the 6 months of follow-up after
successful catheter removal generates a cost-saving of £350
(CONF INT) relative to placebo and £892 (CONF INT) relative
to immediate prostatectomy. Both savings are statistically signif-
icant. Alfuzosin treatment was associated with a lower rate of
prostatectomy after discharge with a successful catheter removal.
CONCLUSIONS: Treating all patients hospitalised with AUR
with alfuzosin decreases the need for surgery and leads to impor-
tant savings for the public health care payer. Future studies
should explore the QoL outcomes of the different strategies.
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OBJECTIVES: To estimate the cost-consequences of treating
women for Stress Urinary Incontinence (SUI) with a pharma-
ceutical intervention—Duloxetine—from the perspective of the
statutory health insurance in Germany. METHODS: A decision-
tree was developed by a panel of clinical experts to model bi-
annual cost-consequences of three treatment strategies: 1) initial
Duloxetine treatment, followed either by continuation of Dulox-
etine, no further treatment or surgical intervention(s); 2) initial
placebo treatment (physician visits), then no further treatment
or surgical intervention(s); and 3) Standard treatment including
surgical intervention(s). Pelvic Floor Exercises were considered
in all arms. Model input for the ﬁrst three months were taken
from one phase 2 and three phase 3 placebo-controlled studies
assessing the efﬁcacy and safety of Duloxetine. 950 patients with
moderate to severe SUI (Incontinence Episodes Frequency, IEF
>= 14/week) were included in the analysis. Success of treatment
was classiﬁed as “full response” (100% reduction in IEF) and
“successful treatment but not dry” (50.0%–99.9% reduction in
IEF). The likelihood of continuation of Duloxetine beyond three
months was based on the patient’s perception of improvement
as assessed by a validated questionnaire. Success rates for the
considered surgical procedures were drawn from the literature
and expert opinion. Diagnosis Related Groups (2004) for
surgery and the Einheitliche Bewertunsmaßstab (EBM) (2003)
for outpatient resource use were taken to derive costs. Placebo
will not present an option in routine practice, but is presented
because of the clinical trial design. RESULTS: Expected bi-
annual costs per women are: Duloxetine treatment 2205€;
placebo treatment 2034€, and 2092€ for standard treatment.
Duloxetine generates a higher probability of avoiding surgery
(36%), compared with placebo (24%) and standard treatment
(20%). CONCLUSIONS: Treating SUI in women with Duloxe-
tine leads to comparable costs to standard treatment. Model lim-
itations include extrapolation of clinical trial data and parameter
input by clinical experts.
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LONG-TERM COST-EFFECTIVENESS MODELLING OF
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OBJECTIVES: The purpose was to develop an economic model
for simulation of the long-term cost-effectiveness of treatment
with ProstaLund Feedback Treatment (PLFT) versus alpha-
blockade in patients with benign prostatic hyperplasia (BPH) 
and lower urinary tract symptoms (LUTS). The model was
applied using information about Swedish treatment practice.
METHODS: Data from published literature, treatment pro-
grams, and ofﬁcial Swedish price lists was used to develop a
disease progression model for patients with BPH and LUTS
according to the International Prostate Symptom Score (IPSS).
Three important time dependent features of disease progression
were regarded in the model: 1) a phase where initial symptoms
are reduced; 2) a stationary post-treatment phase; and 3) a phase
where the probability of a re-intervention will increase. All the
three phases could be adjusted in the model to capture differ-
ences in treatment effects between different treatment options.
Costs and quality adjusted life years (QALY) were calculated for
a period of three years and discounted at 3%. The calculations
were made in Euro (2003 prices). A sensitivity analysis was per-
formed where scenarios regarding baseline disease severity, treat-
ment effects, time horizon, discount rate, age at initiation of
treatment, QALY weights, and assumption about the probabil-
ity of re-treatment were altered. RESULTS: The total three-year
cost of PLFT (including re-treatment) and alfa-blockade was esti-
mated to 2059€ and 1411€, respectively. According to the model
PLFT would result in 0.07–0.10 more QALYs compared to alfa-
blockade resulting in a cost-effectiveness ratio of €6600–9500.
Due to lower future expected costs of PLFT compared to alfa-
blockade the results indicate that PLFT would be cost-saving if
the time perspective is extended to ﬁve years. CONCLUSIONS:
According to the assumptions made in the model, PLFT is cost-
effective compared to alpha-blockade. The main conclusion
remained stable in the sensitivity analysis.
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LOWER MENTAL HEALTH SCORES MEASURED USING THE
SF-36 HEALTH SURVEY IS AN INDEPENDENT PREDICTOR OF
MORTALITY IN YOUNGER PATIENTS RENAL REPLACEMENT
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Hospital Universitario Central de Asturias Institute, Oviedo, Spain
OBJECTIVES: To prospectively evaluate the survival of patients
<65 years who initiated hemodialysis (HD) in our region and to
investigate factors associated with survival. METHODS: All
patients < 65 years who started HD in our region between
January, 2001 and September, 2002 and who remained in renal
replacement therapy (RRT) at least 3 months were included and
followed-up to March, 2004 (N = 78). Patients with severe cog-
nitive deterioration were excluded (n = 1). The health related
quality of life (HRQoL) was evaluated using the SF-36 Health
Survey (Physical-PCS and Mental-MCS Component Summary
Scores) and the Kidney Disease Questionnaire (Physical
Symptom scale-PSS) at 3 months from start and at 1 and 2 years
later. Sociodemographic and clinical data, the Karnofsky Scale
score and a comorbidity index were also collected. SF-36 scores
were standardized using the Spanish general population norms.
Kaplan-Meier survival curves and Cox Proportional hazard
regression model were used for the survival analysis. In order to
adjust the effect of age on mortality the Relative Risk of Mor-
tality (RRM) was calculated using the population rates.
RESULTS: At the end, the 2-year survival rate was 88.3%, but
the RRM fell progressively from 30 in the younger patients
(34–43 years) to 6.33 in the older ones (55–64 years). Kaplan-
Meier analysis showed that those with MCS lower than 40 at 3
months from start and those who had not received a kidney
transplant at the second year of the follow-up had lower survival
(p = 0.0074 and 0.0008 respectively). Cox Proportional hazard
regression model with both variables showed that patients with
MCS lower than 40 had higher mortality risk: hazard ratio =
6.94 (95%CI = 1.34–35.99) p = 0.021. CONCLUSIONS:
Patients between 34 and 43 years showed higher RRM. The
mental aspects of the HRQoL could have an important role in
the survival of patients on RRT under 65 years.
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ELDERLY PATIENTS STARTING RENAL REPLACEMENT
THERAPY (RRT) HAVE LOWER LOSS OF HEALTH RELATED
QUALITY OF LIFE (HRQL) THAN YOUNGER ONES DURING
THE FIRST TWO YEARS
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OBJETIVES: There is already some degree of evidence about the
greater capacity of adaptation to RRT of elderly patients vs. the
